{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:57:06Z","timestamp":1787021826201,"version":"build-2736575974"},"update-to":[{"DOI":"10.1371\/journal.pntd.0011217","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2023,4,6]],"date-time":"2023-04-06T00:00:00Z","timestamp":1680739200000}}],"reference-count":48,"publisher":"Public Library of Science (PLoS)","issue":"3","license":[{"start":{"date-parts":[[2023,3,27]],"date-time":"2023-03-27T00:00:00Z","timestamp":1679875200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32250710141"],"award-info":[{"award-number":["32250710141"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key R&D Program of China","doi-asserted-by":"crossref","award":["2017YFC1601200"],"award-info":[{"award-number":["2017YFC1601200"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.plosntds.org"],"crossmark-restriction":false},"short-container-title":["PLoS Negl Trop Dis"],"abstract":"<jats:p>\n                    <jats:italic>Cryptosporidium parvum<\/jats:italic>\n                    is a globally distributed zoonotic protozoan parasite that causes moderate to severe, sometime deadly, watery diarrhea in humans and animals, for which fully effective treatments are yet unavailable. In studying the mechanism of action of drugs against intracellular pathogens, it is important to validate whether the observed anti-infective activity is attributed to the drug action on the pathogen or host target. For the epicellular parasite\n                    <jats:italic>Cryptosporidium<\/jats:italic>\n                    , we have previously developed a concept that the host cells with significantly increased drug tolerance by transient overexpression of the multidrug resistance protein-1 (MDR1) could be utilized to evaluate whether and how much the observed anti-cryptosporidial activity of an inhibitor was attributed to the inhibitor\u2019s action on the parasite target. However, the transient transfection model was only applicable to evaluating native MDR1 substrates. Here we report an advanced model using stable MDR1-transgenic HCT-8 cells that allows rapid development of novel resistance to non-MDR1 substrates by multiple rounds of drug selection. Using the new model, we successfully validated that nitazoxanide, a non-MDR1 substrate and the only FDA-approved drug to treat human cryptosporidiosis, killed\n                    <jats:italic>C<\/jats:italic>\n                    .\n                    <jats:italic>parvum<\/jats:italic>\n                    by fully (100%) acting on the parasite target. We also confirmed that paclitaxel acted fully on the parasite target, while several other inhibitors including mitoxantrone, doxorubicin, vincristine and ivermectin acted partially on the parasite targets. Additionally, we developed mathematical models to quantify the proportional contribution of the on-parasite-target effect to the observed anti-cryptosporidial activity and to evaluate the relationships between several in vitro parameters, including antiparasitic efficacy (\n                    <jats:italic>EC<\/jats:italic>\n                    <jats:sub>i<\/jats:sub>\n                    ), cytotoxicity (\n                    <jats:italic>TC<\/jats:italic>\n                    <jats:sub>i<\/jats:sub>\n                    ), selectivity index (\n                    <jats:italic>SI<\/jats:italic>\n                    ) and Hill slope (\n                    <jats:italic>h<\/jats:italic>\n                    ). Owning to the promiscuity of the MDR1 efflux pump, the\n                    <jats:italic>MDR1<\/jats:italic>\n                    -transgenic host cell model could be applied to assess the on-parasite-target effects of newly identified hits\/leads, either substrates or non-substrates of MDR1, against\n                    <jats:italic>Cryptosporidium<\/jats:italic>\n                    or other epicellular pathogens.\n                  <\/jats:p>","DOI":"10.1371\/journal.pntd.0011217","type":"journal-article","created":{"date-parts":[[2023,3,27]],"date-time":"2023-03-27T13:36:28Z","timestamp":1679924188000},"page":"e0011217","update-policy":"https:\/\/doi.org\/10.1371\/journal.pntd.corrections_policy","source":"Crossref","is-referenced-by-count":9,"title":["On-target inhibition of Cryptosporidium parvum by nitazoxanide (NTZ) and paclitaxel (PTX) validated using a novel MDR1-transgenic host cell model and algorithms to quantify the effect on the parasite target"],"prefix":"10.1371","volume":"17","author":[{"given":"Bo","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yueyang","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongqiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jigang","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3888-0659","authenticated-orcid":true,"given":"Guan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2023,3,27]]},"reference":[{"issue":"4","key":"pntd.0011217.ref001","doi-asserted-by":"crossref","first-page":"e2831","DOI":"10.1371\/journal.pntd.0002831","article-title":"Distribution and clinical manifestations of Cryptosporidium species and subtypes in HIV\/AIDS patients in Ethiopia","volume":"8","author":"H Adamu","year":"2014","journal-title":"PLoS Negl Trop Dis"},{"issue":"5","key":"pntd.0011217.ref002","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1097\/QAD.0b013e3283437e88","article-title":"Cryptosporidiosis in patients with HIV\/AIDS","volume":"25","author":"M O\u2019Connor R","year":"2011","journal-title":"AIDS"},{"issue":"1","key":"pntd.0011217.ref003","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S1473-3099(14)70772-8","article-title":"A review of the global burden, novel diagnostics, therapeutics, and vaccine targets for cryptosporidium","volume":"15","author":"W Checkley","year":"2015","journal-title":"Lancet Infect Dis"},{"issue":"3","key":"pntd.0011217.ref004","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.pt.2019.12.016","article-title":"A One Health Approach to Tackle Cryptosporidiosis","volume":"36","author":"EA Innes","year":"2020","journal-title":"Trends Parasitol"},{"issue":"5","key":"pntd.0011217.ref005","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.ijpara.2020.03.002","article-title":"Long-term production effects of clinical cryptosporidiosis in neonatal calves","volume":"50","author":"HJ Shaw","year":"2020","journal-title":"Int J Parasitol"},{"issue":"8","key":"pntd.0011217.ref006","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1086\/428839","article-title":"Nitazoxanide: a new thiazolide antiparasitic agent","volume":"40","author":"LM Fox","year":"2005","journal-title":"Clin Infect Dis"},{"issue":"6","key":"pntd.0011217.ref007","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1097\/00001432-200412000-00008","article-title":"New drugs and treatment for cryptosporidiosis","volume":"17","author":"HV Smith","year":"2004","journal-title":"Curr Opin Infect Dis"},{"issue":"14","key":"pntd.0011217.ref008","doi-asserted-by":"crossref","first-page":"7015","DOI":"10.1073\/pnas.1814685116","article-title":"Lysyl-tRNA synthetase as a drug target in malaria and cryptosporidiosis","volume":"116","author":"B Baragana","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"8","key":"pntd.0011217.ref009","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1093\/infdis\/jit327","article-title":"A novel calcium-dependent protein kinase inhibitor as a lead compound for treating cryptosporidiosis","volume":"208","author":"A Castellanos-Gonzalez","year":"2013","journal-title":"J Infect Dis"},{"issue":"7658","key":"pntd.0011217.ref010","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1038\/nature22337","article-title":"A Cryptosporidium PI(4)K inhibitor is a drug candidate for cryptosporidiosis","volume":"546","author":"UH Manjunatha","year":"2017","journal-title":"Nature"},{"issue":"5","key":"pntd.0011217.ref011","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1097\/QCO.0000000000000761","article-title":"Emerging treatment options for cryptosporidiosis","volume":"34","author":"MS Love","year":"2021","journal-title":"Curr Opin Infect Dis"},{"issue":"1","key":"pntd.0011217.ref012","doi-asserted-by":"crossref","first-page":"e0004242","DOI":"10.1371\/journal.pntd.0004242","article-title":"Addressing Cryptosporidium Infection among Young Children in Low-Income Settings: The Crucial Role of New and Existing Drugs for Reducing Morbidity and Mortality","volume":"10","author":"DA Shoultz","year":"2016","journal-title":"PLoS Negl Trop Dis"},{"issue":"1","key":"pntd.0011217.ref013","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s44149-021-00002-y","article-title":"Current status and challenges in drug discovery against the globally important zoonotic cryptosporidiosis","volume":"1","author":"G Zhu","year":"2021","journal-title":"Animal Diseases"},{"key":"pntd.0011217.ref014","first-page":"63","article-title":"Optimization of Methionyl tRNA-Synthetase Inhibitors for Treatment of Cryptosporidium Infection","author":"FS Buckner","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"pntd.0011217.ref015","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1093\/jac\/dkab369","article-title":"Host cells with transient overexpression of MDR1 as a novel in vitro model for evaluating on-target effect for activity against the epicellular Cryptosporidium parasite","volume":"77","author":"B Yang","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"pntd.0011217.ref016","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.drup.2014.11.002","article-title":"The modulation of ABC transporter-mediated multidrug resistance in cancer: a review of the past decade","volume":"18","author":"RJ Kathawala","year":"2015","journal-title":"Drug Resist Updat"},{"issue":"6","key":"pntd.0011217.ref017","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1021\/mp200261n","article-title":"The emergence of drug transporter-mediated multidrug resistance to cancer chemotherapy","volume":"8","author":"CP Wu","year":"2011","journal-title":"Mol Pharm"},{"key":"pntd.0011217.ref018","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.lfs.2018.10.048","article-title":"Structural and functional aspects of P-glycoprotein and its inhibitors","volume":"214","author":"S Mollazadeh","year":"2018","journal-title":"Life Sci"},{"issue":"1","key":"pntd.0011217.ref019","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1042\/bse0500161","article-title":"The P-glycoprotein multidrug transporter","volume":"50","author":"FJ Sharom","year":"2011","journal-title":"Essays Biochem"},{"issue":"1","key":"pntd.0011217.ref020","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0169-409X(02)00169-2","article-title":"Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview","volume":"55","author":"AH Schinkel","year":"2003","journal-title":"Adv Drug Deliv Rev"},{"issue":"4","key":"pntd.0011217.ref021","doi-asserted-by":"crossref","first-page":"597","DOI":"10.2217\/nnm.10.35","article-title":"Nanomedicinal strategies to treat multidrug-resistant tumors: current progress","volume":"5","author":"X Dong","year":"2010","journal-title":"Nanomedicine"},{"issue":"9","key":"pntd.0011217.ref022","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1016\/j.cub.2020.02.077","article-title":"Selecting for Altered Substrate Specificity Reveals the Evolutionary Flexibility of ATP-Binding Cassette Transporters","volume":"30","author":"S Srikant","year":"2020","journal-title":"Curr Biol"},{"key":"pntd.0011217.ref023","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.bcp.2015.12.007","article-title":"Drug-protein hydrogen bonds govern the inhibition of the ATP hydrolysis of the multidrug transporter P-glycoprotein","volume":"101","author":"EE Chufan","year":"2016","journal-title":"Biochem Pharmacol"},{"issue":"4","key":"pntd.0011217.ref024","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1517\/13543776.2011.561784","article-title":"The emerging role of P-glycoprotein inhibitors in drug delivery: a patent review","volume":"21","author":"N Akhtar","year":"2011","journal-title":"Expert Opin Ther Pat"},{"issue":"7","key":"pntd.0011217.ref025","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/s41568-018-0005-8","article-title":"Revisiting the role of ABC transporters in multidrug-resistant cancer","volume":"18","author":"RW Robey","year":"2018","journal-title":"Nat Rev Cancer"},{"issue":"4","key":"pntd.0011217.ref026","doi-asserted-by":"crossref","first-page":"e1009384","DOI":"10.1371\/journal.ppat.1009384","article-title":"Actives from MMV Open Access Boxes? A suggested way forward","volume":"17","author":"K Samby","year":"2021","journal-title":"PLoS Pathog"},{"issue":"3","key":"pntd.0011217.ref027","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1128\/AAC.01159-06","article-title":"Antiparasitic drug nitazoxanide inhibits the pyruvate oxidoreductases of Helicobacter pylori, selected anaerobic bacteria and parasites, and Campylobacter jejuni","volume":"51","author":"PS Hoffman","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"pntd.0011217.ref028","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1093\/oxfordjournals.molbev.a003853","article-title":"Pyruvate: NADP+ oxidoreductase from the mitochondrion of Euglena gracilis and from the apicomplexan Cryptosporidium parvum: a biochemical relic linking pyruvate metabolism in mitochondriate and amitochondriate protists","volume":"18","author":"C Rotte","year":"2001","journal-title":"Mol Biol Evol"},{"key":"pntd.0011217.ref029","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/j.isci.2019.07.003","article-title":"The FDA-Approved Oral Drug Nitazoxanide Amplifies Host Antiviral Responses and Inhibits Ebola Virus","volume":"19","author":"LD Jasenosky","year":"2019","journal-title":"iScience"},{"key":"pntd.0011217.ref030","first-page":"62","article-title":"Nitazoxanide Inhibits Human Norovirus Replication and Synergizes with Ribavirin by Activation of Cellular Antiviral Response","author":"W Dang","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"pntd.0011217.ref031","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1053\/j.gastro.2009.07.056","article-title":"The anti-hepatitis C agent nitazoxanide induces phosphorylation of eukaryotic initiation factor 2alpha via protein kinase activated by double-stranded RNA activation","volume":"137","author":"M Elazar","year":"2009","journal-title":"Gastroenterology"},{"issue":"1","key":"pntd.0011217.ref032","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1093\/jac\/46.1.57","article-title":"Efficacy of nitazoxanide, tizoxanide and tizoxanide glucuronide against Cryptosporidium parvum development in sporozoite-infected HCT-8 enterocytic cells","volume":"46","author":"G Gargala","year":"2000","journal-title":"J Antimicrob Chemother"},{"issue":"11","key":"pntd.0011217.ref033","doi-asserted-by":"crossref","first-page":"4437","DOI":"10.1128\/AAC.49.11.4437-4442.2005","article-title":"Application of quantitative real-time reverse transcription-PCR in assessing drug efficacy against the intracellular pathogen Cryptosporidium parvum in vitro","volume":"49","author":"X Cai","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"pntd.0011217.ref034","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/978-1-4939-9748-0_4","article-title":"Cryptosporidium Oocyst Purification Using Discontinuous Gradient Centrifugation","volume":"2052","author":"MJ Arrowood","year":"2020","journal-title":"Methods Mol Biol"},{"issue":"5","key":"pntd.0011217.ref035","doi-asserted-by":"crossref","first-page":"89S","DOI":"10.1111\/j.1550-7408.1996.tb05015.x","article-title":"Improved purification methods for calf-derived Cryptosporidium parvum oocysts using discontinuous sucrose and cesium chloride gradients","volume":"43","author":"MJ Arrowood","year":"1996","journal-title":"J Eukaryot Microbiol"},{"issue":"2","key":"pntd.0011217.ref036","doi-asserted-by":"crossref","first-page":"314","DOI":"10.2307\/3282084","article-title":"Isolation of Cryptosporidium oocysts and sporozoites using discontinuous sucrose and isopycnic Percoll gradients","volume":"73","author":"MJ Arrowood","year":"1987","journal-title":"J Parasitol"},{"key":"pntd.0011217.ref037","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/978-1-4939-9748-0_18","article-title":"High-Throughput Screening of Drugs Against the Growth of Cryptosporidium parvum In Vitro by qRT-PCR","volume":"2052","author":"H Zhang","year":"2020","journal-title":"Methods Mol Biol"},{"key":"pntd.0011217.ref038","doi-asserted-by":"crossref","first-page":"991","DOI":"10.3389\/fmicb.2015.00991","article-title":"Quantitative RT-PCR assay for high-throughput screening (HTS) of drugs against the growth of Cryptosporidium parvum in vitro","volume":"6","author":"H Zhang","year":"2015","journal-title":"Front Microbiol"},{"key":"pntd.0011217.ref039","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.3389\/fmicb.2019.01999","article-title":"Discovery of Novel Anti-cryptosporidial Activities From Natural Products by in vitro High-Throughput Phenotypic Screening","volume":"10","author":"Z Jin","year":"2019","journal-title":"Front Microbiol"},{"issue":"7","key":"pntd.0011217.ref040","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1093\/infdis\/jix689","article-title":"The Existing Drug Vorinostat as a New Lead Against Cryptosporidiosis by Targeting the Parasite Histone Deacetylases","volume":"217","author":"F Guo","year":"2018","journal-title":"J Infect Dis"},{"issue":"3","key":"pntd.0011217.ref041","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1002\/bit.22968","article-title":"Generation of stable, high-producing CHO cell lines by lentiviral vector-mediated gene transfer in serum-free suspension culture","volume":"108","author":"A Oberbek","year":"2011","journal-title":"Biotechnol Bioeng"},{"issue":"1","key":"pntd.0011217.ref042","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/nrc706","article-title":"Multidrug resistance in cancer: role of ATP-dependent transporters","volume":"2","author":"MM Gottesman","year":"2002","journal-title":"Nat Rev Cancer"},{"issue":"4","key":"pntd.0011217.ref043","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/j.febslet.2005.12.060","article-title":"The molecular basis of multidrug resistance in cancer: the early years of P-glycoprotein research","volume":"580","author":"MM Gottesman","year":"2006","journal-title":"FEBS Lett"},{"issue":"7","key":"pntd.0011217.ref044","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1158\/1078-0432.CCR-11-1590","article-title":"Molecular pathways: regulation and therapeutic implications of multidrug resistance","volume":"18","author":"KG Chen","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"4","key":"pntd.0011217.ref045","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.3892\/ijo.2011.1285","article-title":"Emodin reverses gemcitabine resistance in pancreatic cancer cells via the mitochondrial apoptosis pathway in vitro","volume":"40","author":"DL Liu","year":"2012","journal-title":"Int J Oncol"},{"key":"pntd.0011217.ref046","first-page":"624954","article-title":"Establishment and Characterization of an Irinotecan-Resistant Human Colon Cancer Cell Line","volume":"10","author":"ZX Wu","year":"2020","journal-title":"Front Oncol"},{"issue":"6","key":"pntd.0011217.ref047","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.3892\/ijo.2013.2135","article-title":"Establishment of a 5-fluorouracil-resistant triple-negative breast cancer cell line","volume":"43","author":"K Takahashi","year":"2013","journal-title":"Int J Oncol"},{"issue":"2","key":"pntd.0011217.ref048","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1002\/pst.426","article-title":"Guidelines for accurate EC50\/IC50 estimation","volume":"10","author":"JL Sebaugh","year":"2011","journal-title":"Pharm Stat"}],"updated-by":[{"DOI":"10.1371\/journal.pntd.0011217","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2023,4,6]],"date-time":"2023-04-06T00:00:00Z","timestamp":1680739200000}}],"container-title":["PLOS Neglected Tropical Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pntd.0011217","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,6]],"date-time":"2023-04-06T13:59:00Z","timestamp":1680789540000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pntd.0011217"}},"subtitle":[],"editor":[{"given":"Hamed","family":"Kalani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2023,3,27]]},"references-count":48,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,3,27]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pntd.0011217","relation":{},"ISSN":["1935-2735"],"issn-type":[{"value":"1935-2735","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,27]]}}}